NEW YORK (GenomeWeb) – Clinical-stage biotech Five Prime Therapeutics said today that it is collaborating with Roche to develop immunohistochemistry companion diagnostic assays for use with Five Prime’s investigational drug candidates, bemarituzumab, an anti-FGFR2b antibody, and FPA150, a B7-H4 antibody.
Financial terms of the agreement were not disclosed.
The firms are collaborating to develop, validate, and commercialize a tissue-based IHC CDx assay to help identify patients whose tumors overexpress the FGFR2b protein and are eligible for treatment with bemarituzumab.